Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PMM2 CRISPR/Cas9 KO Plasmid (h): sc-406428
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PMM2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PMM2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PMM2 Antibody (2A5): sc-517179
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PMM2 CRISPR/Cas9 KO Plasmid (h) | sc-406428 | 20 µg | $397.00 |
Overview
PMM2 encodes phosphomannomutase 2, a cytosolic enzyme that interconverts mannose-6-phosphate and mannose-1-phosphate to support GDP-mannose production and N-linked glycosylation. Through its role in glycan precursor biosynthesis, PMM2 influences protein folding, quality control, secretion, and extracellular matrix interactions across multiple cell types. Reduced PMM2 activity is linked to congenital disorders of glycosylation, where impaired glycoprotein maturation perturbs signaling, trafficking, and organ development. In cell-based models, PMM2 function is commonly interrogated to dissect glycosylation-dependent proteostasis and stress-response pathways, including ER homeostasis.
PMM2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PMM2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PMM2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PMM2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PMM2 protein expression.
This CRISPR knockout system enables efficient generation of PMM2-deficient cell models for investigation of PMM2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PMM2 exon(s) critical for PMM2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PMM2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PMM2 CRISPR/Cas9 KO Plasmid (h) and PMM2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PMM2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PMM2 HDR Plasmid (h) and PMM2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PMM2 homology arms to support homology-directed repair at defined PMM2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.